NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $8 PT on Matinas BioPharma Holdings, Inc. (NYSE: MTNB)

Aegis Capital has reiterated its ‘Buy’ rating and price target of $8 on Matinas BioPharma (NYSE: MTNB). Aegis cited positive results from the company’s phase 1 clinical trial of the safety, tolerability and pharmacokinetics of MAT2501, its cochleated version of amikacin used to treat different types of chronic and acute bacterial infections. Although mild adverse events on the gastrointestinal system were reported, they decreased when the drug was administered with food. No serious adverse events were reported. Aegis also noted recent, critical comments posted to a financial website, which the analyst believes to be incorrect and responsible for recent volatility in Matinas’ stock.

For more information, visit

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. The company’s proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The company’s lead drug candidate MAT2203 is an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent). MAT2203 is currently being studied in two separate phase 2 studies with topline results of each trial expected to be announced in the second quarter of 2017. MAT2501, the company’s orally-administered encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections, reported positive topline data from the phase 1 single-ascending dose study in healthy volunteers. Matinas is advancing its MAT2501 phase 1 program in preparation of a phase 2 study in patients.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s